Sildenafil for Antenatal Treatment of Congenital Diaphragmatic Hernia: from Bench to Bedside.

CONCLUSION: There is preclinical evidence that maternally administered sildenafil prevents the vascular changes that lead to PPH in CDH newborns. The phase I/IIb clinical study together with the p-PBPK model will define the maternal dose needed for a therapeutic effect in the foetus. Foetal safety will be investigated both in the clinical study and in the sheep. The final step will be a multicentre, randomized, placebo-controlled trial.
PMID: 30894101 [PubMed - as supplied by publisher]

Source: Current Pharmaceutical Design - March 19, 2019 Category: Drugs & Pharmacology Authors: Russo FM, De Bie F, Hodges R, Flake A, Deprest J Tags: Curr Pharm Des Source Type: research